Evidence map›Paper›PMID 40613410›Full record

ReviewRevista de neurologia2025

Gepants: Key Features of A Potent Therapeutic Option and Considerations in The Latin American Context.

David Ríos Patiño, Julián Cuartas Zapata, Adolfo León Vélez Aguirre

Abstract readReview
In one paragraph

Review in Revista de neurologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

David Ríos PatiñoServicio de Neurologia, Fundación Instituto Neurológico de Colombia, 050010 Medellín, Colombia.
Julián Cuartas ZapataServicio de Neurologia, Fundación Instituto Neurológico de Colombia, 050010 Medellín, Colombia.
Adolfo León Vélez AguirreServicio de Neurologia, Fundación Instituto Neurológico de Colombia, 050010 Medellín, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is a complex condition when considered from the perspective of its pathophysiology. Moreover, it is highly prevalent and of priority interest in public health. Gepants are a highly-effective and specific therapeutic option, although their recent arrival in Latin America raises particular questions and expectations. A narrative review of the four medications available outside Latin America at this time is provided and the main considerations that should be borne in mind before and during their adoption are presented. Appropriate patient selection and marketing cost will be key determinants for their consolidation as an alternative to traditional medications used in migraine.

Indexed as

Migraine DisordersTryptaminesHumansLatin AmericaTryptaminescalcitonin gene-related peptidegepantsmigrainetherapeutics

Identifiers

PMID40613410
PMCPMC12231511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.